People living with Human Immunodeficiency Virus (PLW-HIV) on anti-retroviral therapy are more likely to develop tuberculosis as compared to people without HIV. The objective of the study is to evaluate the risk factors, prevalence, and management pattern of Anti-tubercular therapy-induced hepatitis (ATT-IH) in PLW-HIV with Anti-Retroviral Therapy (ART) in comparison with HIV-SNP.
Methodology
A retrospective observational cohort study was conducted at a university teaching hospital for Anti-tubercular therapy-induced hepatitis ATT-IH. Patients were screened based on International Classification of Diseases codes 10. A total of N = 431 patients with ATT-IH (250 males and 181 females) were included in the study. The severity grading of ATT-IH was assessed by Liver Tox. The risk factors associated with ATT-IH in HIV-SPP and HIV-SNP were assessed and determined at a p value <0.05.
Results
Out of 431 patients with ATT-IH, 231 patients experienced ATT-IH in the HIV-SP group and 200 patients in the HIV-SN group. Zero-inflated regression analysis identified risk factors for ATT-IH in HIV-SPP in comparison with HIV-SNP, including BMI, hepatitis B, and smoking habits. The prevalence of ATT-IH in HIV-SPP was 53.6% and 46.4% in HIV-SNP. A higher incidence of 23 (10 %) of ATT-IH was reported with the Tenofovir + Lamivudine + Lopinavir+ Ritonavir ART regimen.
Conclusion
Clinicians must focus on early detection of risk factors for ATT-IH in HIV-SPP in comparison with HIV-SNP to prevent significant hepatic complications.
SahaAShanthiFXMWinstonAB, et al.Prevalence of hepatotoxicity from antituberculosis therapy: a five-year experience from South India. J Prim Care Community Health2016; 7(3): 171–174.
3.
Central TB Division MoHaFW, Government of India. National guidelines for management of drug resistant TB. Government of India, 2025.
4.
ResearchICM. Drug Sensitive-TB treatment as per NTEP adult TB guidelines. Indian Council of Medical Research, 2022.
5.
Ministry of Health and Family Welfare GoI. National tuberculosis elimination programme. Directorate general of health services. Government of India, 2024.
6.
MollaYWubetuMDessieB. Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, Ethiopia. Hepat Med2021; 13: 1–8.
7.
RajeshRVidyasagarSVarmaDM, et al.A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients. Int J Risk Saf Med2013; 25(1): 53–65.
8.
WHO HIV/AIDS Programme. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, Recommendation for a public health approach. 2nd ed. 2016. [Available from]: https://www.who.int/hiv/pub/arv/arv-2016/en/
9.
Araújo-MarizCLopesEPAcioli-SantosB, et al.Hepatotoxicity during treatment for tuberculosis in people living with HIV/AIDS. PLoS One2016; 11(6): e0157725.
10.
ManosuthiWWiboonchutikulSSungkanuparphS. Integrated therapy for HIV and tuberculosis. AIDS Res Ther2016; 13: 1–12.
11.
AaronLSaadounDCalatroniI, et al.Tuberculosis in HIV-Infected patients: a comprehensive review. Clin Microbiol Infect2004; 10(5): 388–398.
12.
BajpaiSJoshiK. Hepatotoxicity in HIV patients, an observational study in patients from tertiary care centre of Western India. J Assoc Phys India2017; 65: 47–49.
13.
de Moura TomichLGMNúñezMMendes-CorreaMC. Drug-induced liver injury in hospitalized HIV patients: high incidence and association with drugs for tuberculosis. Ann Hepatol2016; 14(6): 888–894.
14.
MoPZhuQTeterC, et al.Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus. Int J Infect Dis2014; 28: 95–100.
15.
NissapatornVKuppusamyIJosephineF, et al.Tuberculosis: a resurgent disease in immunosuppressed patients. Southeast Asian J Trop Med Publ Health2006; 37: 153–160.
16.
IsaSEEAShehuNYIdokoP, et al.Antituberculosis drugs and hepatotoxicity among hospitalized patients in jos, Nigeria. Int J Mycobacteriol2016; 5(1): 21–26.
17.
RajeshRSonikaSSudhaV, et al.Association between medication adherence outcomes and adverse drug reactions to highly active antiretroviral therapy in Indian human immunodeficiency virus-positive patients. J Young Pharm2012; 4(4): 250–260.
Clinical and research information on drug-Induced liver injury, United States national library of Medicine[Internet]. 2017. Available from: https://livertox.nih.gov/Severity.html
20.
Hassen AliABelachewTYamiA, et al.Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at jimma University Hospital, Ethiopia: nested case-control study. PLoS One2013; 8(5): e64622.
21.
AnandASethAPaulM, et al.Risk factors of hepatotoxicity during anti-tuberculosis treatment. Med J Armed Forces India2006; 62(1): 45–49.
22.
Fernandez-VillarASopenaBFernandez-VillarJ, et al.The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tubercul Lung Dis2004; 8(12): 1499–1505.
23.
ZhangFZhangFQinM, et al.Alcohol consumption as a risk factor for anti-tuberculosis drug induced liver injury: a systematic review and meta-analysis. Microb Pathog2024; 196: 107003.
24.
ShamannaSBNaikRRRHamideA. Causes of liver disease and its outcome in HIV-Infected individuals. Indian J Gastroenterol2016; 35: 310–314.
25.
AvihingsanonAvan der LugtJSingphoreU, et al.Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study. AIDS Res Hum Retrovir2012; 28(10): 1170–1176.
26.
MohammedOAlemayehuEBisetegnH, et al.Prevalence of hepatotoxicity among HIV-Infected patients in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis2022; 22(1): 826.
27.
SinghKPCraneMAudsleyJ, et al.HIV-Hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS2017; 31(15): 2035–2052.
28.
PuriPSharmaPLolusareA, et al.Liver function tests abnormalities and hepatitis B virus & hepatitis C virus co-infection in human immunodeficiency virus (HIV)-Infected patients in India. J Clin Exp Hepatol2017; 7(1): 1–8.
29.
WangNChenXHaoZ, et al.Incidence and temporal trend of antituberculosis drug‐induced liver injury: a systematic review and meta‐analysis. J Trop Med2022; 2022(1): 8266878.
30.
SharmaSKBalamuruganASahaPK, et al.Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med2002; 166(7): 916–919.
31.
PolSLebraPVallet-PichardA. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis2004; 38(Supplement_2): S65–S72.
32.
NgouleunWNyaPCBPiemeAC, et al.Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment. Int J Mycobacteriol2016; 5(4): 482–488.
33.
AbbaraAChittySRoeJK, et al.Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect Dis2017; 17: 1–9.
34.
El BouazziOHammiSBourkadiJE, et al.First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors. Pan Afr Med J2016; 25: 167.
35.
PukenyteELescureF-XReyD, et al.Incidence of and risk factors for severe liver toxicity in HIV-Infected patients on anti-tuberculosis treatment. Int J Tubercul Lung Dis2007; 11(1): 78–84.
36.
LemoineMLacombeKBastardJP, et al.Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-Monoinfected patients. AIDS2017; 31(14): 1955–1964.
37.
SegalLNClementeJCLiY, et al.Anaerobic bacterial fermentation products increase tuberculosis risk in antiretroviral-drug-treated HIV patients. Cell Host Microbe2017; 21(4): 530–537.
38.
HoffmannCJCharalambousSThioCL, et al.Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS2007; 21(10): 1301–1308.
SunQZhangQGuJ, et al.Prevalence, risk factors, management, and treatment outcomes of first‐line antituberculous drug‐induced liver injury: a prospective cohort study. Pharmacoepidemiol Drug Saf2016; 25(8): 908–917.
41.
TedlaZNyirendaSPeelerC, et al.Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in HIV-Infected adults in Botswana. Am J Respir Crit Care Med2010; 182(2): 278–285.
42.
NaderLAde MattosAAPiconPD, et al.Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?Ann Hepatol2010; 9(1): 70–74.
43.
YimerGGryMAmogneW, et al.Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in Ethiopian patients. PLoS One2014; 9(4): e94271.
44.
PatelAPatelKPatelJ, et al.Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr2004; 37(1): 1166–1169.
45.
Dos SantosAPGPachecoAStaviackA, et al.Safety and effectiveness of HAART in tuberculosis-HIV co-infected patients in Brazil. Int J Tubercul Lung Dis2013; 17(2): 192–197.
46.
BoylesTBerhanuRHGogelaN, et al.Management of drug-induced liver injury in people with HIV treated for tuberculosis: 2024 update. South Afr J HIV Med2024; 25(1): 1558.
47.
SiddalingaiahNChawlaKNagarajaSB, et al.Risk factors for the development of tuberculosis among the pediatric population: a systematic review and meta-analysis. Eur J Pediatr2023; 182(7): 3007–3019.
48.
ShahGHEwetolaREtheredgeG, et al.Kilundu A. Risk factors for TB/HIV coinfection and consequences for patient outcomes: evidence from 241 clinics in the democratic republic of Congo. Int J Environ Res Publ Health2021; 18(10): 5165.
49.
CooreyNJKensittLDaviesJ, et al.Risk factors for TB in Australia and their association with delayed treatment completion. The international journal of tuberculosis and lung disease. Int J Tubercul Lung Dis2022; 26(5): 399–405.
50.
RanganathTSKishoreSGReddyR, et al.Risk factors for non-adherence among people with HIV-Associated TB in Karnataka, India: a case–control study. Indian J Tubercul2022; 69(1): 65–72.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
